Analytical dilemmas in lupus anticoagulant detection

Accurate lupus anticoagulant (LA) detection is crucial to antiphospholipid syndrome (APS) diagnosis. Detection is based on LA functional behavior in coagulation assays irrespective of epitope specificity. LA screening tests employ dilute phospholipids to accentuate in vitro inhibition by LAs, althou...

Full description

Bibliographic Details
Main Author: Gary W. Moore
Format: Article
Language:English
Published: Open Exploration Publishing Inc. 2023-08-01
Series:Exploration of Immunology
Subjects:
Online Access:https://www.explorationpub.com/Journals/ei/Article/1003104
_version_ 1797691852372049920
author Gary W. Moore
author_facet Gary W. Moore
author_sort Gary W. Moore
collection DOAJ
description Accurate lupus anticoagulant (LA) detection is crucial to antiphospholipid syndrome (APS) diagnosis. Detection is based on LA functional behavior in coagulation assays irrespective of epitope specificity. LA screening tests employ dilute phospholipids to accentuate in vitro inhibition by LAs, although they are not LA-specific and can be elevated by other coagulation abnormalities. Elevated screening tests are reflexed to mixing tests to distinguish between factor deficiency and inhibition. Confirmatory tests with high phospholipid concentration swamp LA to generate shorter clotting times than screening tests, whilst prolongation persists with non-phospholipid-dependent inhibitors. LA heterogeneity means that no single screening test detects every LA and the screen/mix/confirm medley must be applied to at least two assay types, usually dilute Russell’s viper venom time (dRVVT) and an LA-sensitive activated partial thromboplastin time (aPTT). Most laboratories restrict LA testing to these two assays, yet others, such as dilute prothrombin time (dPT), can perform with equal diagnostic efficacy, and additionally detect LA unreactive with dRVVT and aPTT. Converting clotting times to normalized ratios improves assay performance, and practitioners must choose between normal pooled plasma (NPP) clotting time denominators to reflect on-the-day assay performance, or reference interval (RI) mean clotting times to negate the effects of NPP variation. Cut-offs can be generated parametrically from normally distributed data, or different percentiles applied depending on the preferred balance between sensitivity and specificity. Sourcing sufficient donors for accurate cut-off estimations is problematic and transference exercises can be undertaken on low donor numbers. Analytical limitations of mixing tests have led to the adoption of alternative algorithms to the screen/mix/confirm test order, whilst some continue to rigidly apply the latter despite those limitations. Strategies to reduce or eliminate the effects of therapeutic anticoagulation have limitations, whilst the Taipan snake venom time (TSVT) screening test with an ecarin time (ET) confirmatory test is insensitive to vitamin K antagonist (VKA) and direct activated factor X anticoagulation.
first_indexed 2024-03-12T02:19:20Z
format Article
id doaj.art-822bb8fc6a7846fba4268c1eb122d153
institution Directory Open Access Journal
issn 2768-6655
language English
last_indexed 2024-03-12T02:19:20Z
publishDate 2023-08-01
publisher Open Exploration Publishing Inc.
record_format Article
series Exploration of Immunology
spelling doaj.art-822bb8fc6a7846fba4268c1eb122d1532023-09-06T06:21:00ZengOpen Exploration Publishing Inc.Exploration of Immunology2768-66552023-08-013430032410.37349/ei.2023.00104Analytical dilemmas in lupus anticoagulant detectionGary W. Moore0https://orcid.org/0000-0002-2987-281XSpecialist Haemostasis Unit, Department of Haematology, Cambridge University Hospitals NHS Foundation Trust, CB2 0QQ Cambridge, UK; Department of Natural Sciences, Faculty of Science and Technology, Middlesex University, NW4 4BT London, UKAccurate lupus anticoagulant (LA) detection is crucial to antiphospholipid syndrome (APS) diagnosis. Detection is based on LA functional behavior in coagulation assays irrespective of epitope specificity. LA screening tests employ dilute phospholipids to accentuate in vitro inhibition by LAs, although they are not LA-specific and can be elevated by other coagulation abnormalities. Elevated screening tests are reflexed to mixing tests to distinguish between factor deficiency and inhibition. Confirmatory tests with high phospholipid concentration swamp LA to generate shorter clotting times than screening tests, whilst prolongation persists with non-phospholipid-dependent inhibitors. LA heterogeneity means that no single screening test detects every LA and the screen/mix/confirm medley must be applied to at least two assay types, usually dilute Russell’s viper venom time (dRVVT) and an LA-sensitive activated partial thromboplastin time (aPTT). Most laboratories restrict LA testing to these two assays, yet others, such as dilute prothrombin time (dPT), can perform with equal diagnostic efficacy, and additionally detect LA unreactive with dRVVT and aPTT. Converting clotting times to normalized ratios improves assay performance, and practitioners must choose between normal pooled plasma (NPP) clotting time denominators to reflect on-the-day assay performance, or reference interval (RI) mean clotting times to negate the effects of NPP variation. Cut-offs can be generated parametrically from normally distributed data, or different percentiles applied depending on the preferred balance between sensitivity and specificity. Sourcing sufficient donors for accurate cut-off estimations is problematic and transference exercises can be undertaken on low donor numbers. Analytical limitations of mixing tests have led to the adoption of alternative algorithms to the screen/mix/confirm test order, whilst some continue to rigidly apply the latter despite those limitations. Strategies to reduce or eliminate the effects of therapeutic anticoagulation have limitations, whilst the Taipan snake venom time (TSVT) screening test with an ecarin time (ET) confirmatory test is insensitive to vitamin K antagonist (VKA) and direct activated factor X anticoagulation.https://www.explorationpub.com/Journals/ei/Article/1003104activated partial thromboplastin timeantiphospholipid antibodiesconfirmatory testdilute prothrombin timedilute russell’s viper venom timemixing testscreening testtaipan snake venom time
spellingShingle Gary W. Moore
Analytical dilemmas in lupus anticoagulant detection
Exploration of Immunology
activated partial thromboplastin time
antiphospholipid antibodies
confirmatory test
dilute prothrombin time
dilute russell’s viper venom time
mixing test
screening test
taipan snake venom time
title Analytical dilemmas in lupus anticoagulant detection
title_full Analytical dilemmas in lupus anticoagulant detection
title_fullStr Analytical dilemmas in lupus anticoagulant detection
title_full_unstemmed Analytical dilemmas in lupus anticoagulant detection
title_short Analytical dilemmas in lupus anticoagulant detection
title_sort analytical dilemmas in lupus anticoagulant detection
topic activated partial thromboplastin time
antiphospholipid antibodies
confirmatory test
dilute prothrombin time
dilute russell’s viper venom time
mixing test
screening test
taipan snake venom time
url https://www.explorationpub.com/Journals/ei/Article/1003104
work_keys_str_mv AT garywmoore analyticaldilemmasinlupusanticoagulantdetection